Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 28008155)

  • 1. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC.
    Singleton KR; Hinz TK; Kleczko EK; Marek LA; Kwak J; Harp T; Kim J; Tan AC; Heasley LE
    Cancer Res; 2015 Oct; 75(20):4398-406. PubMed ID: 26359452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance to FGFR1-targeted therapy leads to autophagy via TAK1/AMPK activation in gastric cancer.
    Peng R; Chen Y; Wei L; Li G; Feng D; Liu S; Jiang R; Zheng S; Chen Y
    Gastric Cancer; 2020 Nov; 23(6):988-1002. PubMed ID: 32617693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ceritinib increases sensitivity of AKT inhibitors to gastric cancer.
    Wang J; Xu X; Wang T; Guo Q; Dai X; Guo H; Zhang W; Cheng S; Chen X; Ding L
    Eur J Pharmacol; 2021 Apr; 896():173879. PubMed ID: 33515539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
    Pearson A; Smyth E; Babina IS; Herrera-Abreu MT; Tarazona N; Peckitt C; Kilgour E; Smith NR; Geh C; Rooney C; Cutts R; Campbell J; Ning J; Fenwick K; Swain A; Brown G; Chua S; Thomas A; Johnston SRD; Ajaz M; Sumpter K; Gillbanks A; Watkins D; Chau I; Popat S; Cunningham D; Turner NC
    Cancer Discov; 2016 Aug; 6(8):838-851. PubMed ID: 27179038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma.
    Maehara O; Suda G; Natsuizaka M; Ohnishi S; Komatsu Y; Sato F; Nakai M; Sho T; Morikawa K; Ogawa K; Shimazaki T; Kimura M; Asano A; Fujimoto Y; Ohashi S; Kagawa S; Kinugasa H; Naganuma S; Whelan KA; Nakagawa H; Nakagawa K; Takeda H; Sakamoto N
    Carcinogenesis; 2017 Oct; 38(11):1073-1083. PubMed ID: 28927233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of fibroblast growth factor receptor with AZD4547 mitigates juvenile nasopharyngeal angiofibroma.
    Le T; New J; Jones JW; Usman S; Yalamanchali S; Tawfik O; Hoover L; Bruegger DE; Thomas SM
    Int Forum Allergy Rhinol; 2017 Oct; 7(10):973-979. PubMed ID: 28707818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of gemcitabine plus an anti-FGFR inhibitor can have a synergistic antitumor effect on FGF-activating cholangiocarcinoma.
    Ito Y; Yamada D; Kobayashi S; Sasaki K; Iwagami Y; Tomimaru Y; Asaoka T; Noda T; Takahashi H; Shimizu J; Doki Y; Eguchi H
    Cancer Lett; 2024 Jul; 595():216997. PubMed ID: 38801887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
    Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
    Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formation of a polarised primitive endoderm layer in embryoid bodies requires fgfr/erk signalling.
    Doughton G; Wei J; Tapon N; Welham MJ; Chalmers AD
    PLoS One; 2014; 9(4):e95434. PubMed ID: 24752320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming fusions of FGFR and TACC genes in human glioblastoma.
    Singh D; Chan JM; Zoppoli P; Niola F; Sullivan R; Castano A; Liu EM; Reichel J; Porrati P; Pellegatta S; Qiu K; Gao Z; Ceccarelli M; Riccardi R; Brat DJ; Guha A; Aldape K; Golfinos JG; Zagzag D; Mikkelsen T; Finocchiaro G; Lasorella A; Rabadan R; Iavarone A
    Science; 2012 Sep; 337(6099):1231-5. PubMed ID: 22837387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of FBXO31-mediated degradation of DUSP6 dysregulates ERK and PI3K-AKT signaling and promotes prostate tumorigenesis.
    Duan S; Moro L; Qu R; Simoneschi D; Cho H; Jiang S; Zhao H; Chang Q; de Stanchina E; Arbini AA; Pagano M
    Cell Rep; 2021 Oct; 37(3):109870. PubMed ID: 34686346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GLI1 reduces drug sensitivity by regulating cell cycle through PI3K/AKT/GSK3/CDK pathway in acute myeloid leukemia.
    Zhou C; Du J; Zhao L; Liu W; Zhao T; Liang H; Fang P; Zhang K; Zeng H
    Cell Death Dis; 2021 Mar; 12(3):231. PubMed ID: 33658491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
    De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
    Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor receptors 1 and 4 combined with lymph node metastasis predicts poor prognosis in oral cancer.
    Gu ZY; Zhou R; Hong D; Han Y; Wang LZ; Li J; Zhang ZY; Shi CJ
    Oral Dis; 2024 Apr; 30(3):1004-1017. PubMed ID: 36938639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases.
    Wan X; Corn PG; Yang J; Palanisamy N; Starbuck MW; Efstathiou E; Li Ning Tapia EM; Zurita AJ; Aparicio A; Ravoori MK; Vazquez ES; Robinson DR; Wu YM; Cao X; Iyer MK; McKeehan W; Kundra V; Wang F; Troncoso P; Chinnaiyan AM; Logothetis CJ; Navone NM
    Sci Transl Med; 2014 Sep; 6(252):252ra122. PubMed ID: 25186177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CHMFL-BMX-078, a BMX inhibitor, overcomes the resistance of melanoma to vemurafenib via inhibiting AKT pathway.
    Jiang S; Jiang T; Huang H; Chen X; Li L; Wang Z; Fei J; Liu C; Liu Z; Cheng Y
    Chem Biol Interact; 2022 Jan; 351():109747. PubMed ID: 34813779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.
    Eke I; Makinde AY; Aryankalayil MJ; Sandfort V; Palayoor ST; Rath BH; Liotta L; Pierobon M; Petricoin EF; Brown MF; Stommel JM; Ahmed MM; Coleman CN
    Mol Cancer Ther; 2018 Feb; 17(2):355-367. PubMed ID: 28802252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition.
    Fischer H; Taylor N; Allerstorfer S; Grusch M; Sonvilla G; Holzmann K; Setinek U; Elbling L; Cantonati H; Grasl-Kraupp B; Gauglhofer C; Marian B; Micksche M; Berger W
    Mol Cancer Ther; 2008 Oct; 7(10):3408-19. PubMed ID: 18852144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.
    Lamont FR; Tomlinson DC; Cooper PA; Shnyder SD; Chester JD; Knowles MA
    Br J Cancer; 2011 Jan; 104(1):75-82. PubMed ID: 21119661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.